PKCα-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells
Author:
Mauro Annunziata1, Ciccarelli Carmela1, De Cesaris Paola1, Scoglio Arianna2, Bouché Marina2, Molinaro Mario2, Aquino Angelo3, Zani Bianca Maria1
Affiliation:
1. Department of Experimental Medicine, University of L'Aquila, Via Vetoio,Coppito II, 67100 L'Aquila, Italy 2. Department of Histology and Embryology, University of Rome `La Sapienza', Via Scarpa 14, 00161 Rome, Italy 3. Department of Neuroscience, Section of Pharmacology and Medical Oncology,University of Rome Tor Vergata, Via di Tor Vergata 135, 00133 Rome,Italy
Abstract
We have previously suggested that PKCα has a role in 12-O-Tetradecanoylphorbol-13-acetate (TPA)-mediated growth arrest and myogenic differentiation in human embryonal rhabdomyosarcoma cells (RD).
Here, by monitoring the signalling pathways triggered by TPA, we demonstrate that PKCα mediates these effects by inducing transient activation of c-Jun N-terminal protein kinases (JNKs) and sustained activation of both p38 kinase and extracellular signal-regulated kinases (ERKs) (all referred to as MAPKs). Activation of MAPKs following ectopic expression of constitutively active PKCα, but not its dominant-negative form, is also demonstrated.
We investigated the selective contribution of MAPKs to growth arrest and myogenic differentiation by monitoring the activation of MAPK pathways, as well as by dissecting MAPK pathways using MEK1/2 inhibitor (UO126), p38 inhibitor (SB203580) and JNK and p38 agonist (anisomycin) treatments. Growth-arresting signals are triggered either by transient and sustained JNK activation (by TPA and anisomycin, respectively) or by preventing both ERK and JNK activation (UO126) and are maintained, rather than induced, by p38. We therefore suggest a key role for JNK in controlling ERK-mediated mitogenic activity. Notably, sarcomeric myosin expression is induced by both TPA and UO126 but is abrogated by the p38 inhibitor. This finding indicates a pivotal role for p38 in controlling the myogenic program. Anisomycin persistently activates p38 and JNKs but prevents myosin expression induced by TPA. In accordance with this negative role, reactivation of JNKs by anisomycin, in UO126-pre-treated cells, also prevents myosin expression. This indicates that,unlike the transient JNK activation that occurs in the TPA-mediated myogenic process, long-lasting JNK activation supports the growth-arrest state but antagonises p38-mediated myosin expression. Lastly, our results with the MEK inhibitor suggest a key role of the ERK pathway in regulating myogenic-related morphology in differentiated RD cells.
Publisher
The Company of Biologists
Reference67 articles.
1. Aguanno, S., Bouche, M., Adamo, S. and Molinaro, M.(1990). 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of a human rhabdomyosarcoma cell line. Cancer Res.50, 3377-3382. 2. Aquino, A., Warren, B. S., Omichinski, J., Hartman, K. D. and Glazer, R. I. (1990). Protein kinase C-gamma is present in adriamycin resistant HL-60 leukemia cells. Biochem. Biophys. Res. Commun.166, 723-728. 3. Baier-Bitterlich, G., Uberall, F., Bauer, B., Fresser, F.,Wachter, H., Grunicke, H., Utermann, G., Altman, A. and Baier, G.(1996). Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Mol. Cell Biol.16, 1842-1850. 4. Bengal, E., Ransone, L., Scharfmann, R., Dwarki, V. J.,Tapscott, S. J., Weintraub, H. and Verma, I. M. (1992). Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell68, 507-519. 5. Bennett, A. M. and Tonks, N. K. (1997). Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science278, 1288-1291.
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|